Cargando…

The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids

BACKGROUND: Chronic cerebral hypoperfusion (CCH) underlies secondary brain injury following certain metabolic disorders and central nervous system (CNS) diseases. Dysregulation of the microbiota-gut-brain axis can exacerbate various CNS disorders through aberrantly expressed metabolites such as shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Weiping, Su, Jiabin, Gao, Xinjie, Yang, Heng, Weng, Ruiyuan, Ni, Wei, Gu, Yuxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013454/
https://www.ncbi.nlm.nih.gov/pubmed/35430804
http://dx.doi.org/10.1186/s40168-022-01255-6
_version_ 1784687998429822976
author Xiao, Weiping
Su, Jiabin
Gao, Xinjie
Yang, Heng
Weng, Ruiyuan
Ni, Wei
Gu, Yuxiang
author_facet Xiao, Weiping
Su, Jiabin
Gao, Xinjie
Yang, Heng
Weng, Ruiyuan
Ni, Wei
Gu, Yuxiang
author_sort Xiao, Weiping
collection PubMed
description BACKGROUND: Chronic cerebral hypoperfusion (CCH) underlies secondary brain injury following certain metabolic disorders and central nervous system (CNS) diseases. Dysregulation of the microbiota-gut-brain axis can exacerbate various CNS disorders through aberrantly expressed metabolites such as short-chain fatty acids (SCFAs). Yet, its relationship with CCH remains to be demonstrated. And if so, it is of interest to explore whether restoring gut microbiota to maintain SCFA metabolism could protect against CCH. RESULTS: Rats subjected to bilateral common carotid artery occlusion (BCCAO) as a model of CCH exhibited cognitive impairment, depressive-like behaviors, decreased gut motility, and compromised gut barrier functions. The 16S ribosomal RNA gene sequencing revealed an abnormal gut microbiota profile and decreased relative abundance of some representative SCFA producers, with the decreased hippocampal SCFAs as the further evidence. Using fecal microbiota transplantation (FMT), rats recolonized with a balanced gut microbiome acquired a higher level of hippocampal SCFAs, as well as decreased neuroinflammation when exposed to lipopolysaccharide. Healthy FMT promoted gut motility and gut barrier functions, and improved cognitive decline and depressive-like behaviors by inhibiting hippocampal neuronal apoptosis in BCCAO rats. Long-term SCFA supplementation further confirmed its neuroprotective effect in terms of relieving inflammatory response and hippocampal neuronal apoptosis following BCCAO. CONCLUSION: Our results demonstrate that modulating the gut microbiome via FMT can ameliorate BCCAO-induced gut dysbiosis, cognitive decline, and depressive-like behaviors, possibly by enhancing the relative abundance of SCFA-producing floras and subsequently increasing SCFA levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01255-6.
format Online
Article
Text
id pubmed-9013454
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90134542022-04-18 The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids Xiao, Weiping Su, Jiabin Gao, Xinjie Yang, Heng Weng, Ruiyuan Ni, Wei Gu, Yuxiang Microbiome Research BACKGROUND: Chronic cerebral hypoperfusion (CCH) underlies secondary brain injury following certain metabolic disorders and central nervous system (CNS) diseases. Dysregulation of the microbiota-gut-brain axis can exacerbate various CNS disorders through aberrantly expressed metabolites such as short-chain fatty acids (SCFAs). Yet, its relationship with CCH remains to be demonstrated. And if so, it is of interest to explore whether restoring gut microbiota to maintain SCFA metabolism could protect against CCH. RESULTS: Rats subjected to bilateral common carotid artery occlusion (BCCAO) as a model of CCH exhibited cognitive impairment, depressive-like behaviors, decreased gut motility, and compromised gut barrier functions. The 16S ribosomal RNA gene sequencing revealed an abnormal gut microbiota profile and decreased relative abundance of some representative SCFA producers, with the decreased hippocampal SCFAs as the further evidence. Using fecal microbiota transplantation (FMT), rats recolonized with a balanced gut microbiome acquired a higher level of hippocampal SCFAs, as well as decreased neuroinflammation when exposed to lipopolysaccharide. Healthy FMT promoted gut motility and gut barrier functions, and improved cognitive decline and depressive-like behaviors by inhibiting hippocampal neuronal apoptosis in BCCAO rats. Long-term SCFA supplementation further confirmed its neuroprotective effect in terms of relieving inflammatory response and hippocampal neuronal apoptosis following BCCAO. CONCLUSION: Our results demonstrate that modulating the gut microbiome via FMT can ameliorate BCCAO-induced gut dysbiosis, cognitive decline, and depressive-like behaviors, possibly by enhancing the relative abundance of SCFA-producing floras and subsequently increasing SCFA levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01255-6. BioMed Central 2022-04-17 /pmc/articles/PMC9013454/ /pubmed/35430804 http://dx.doi.org/10.1186/s40168-022-01255-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xiao, Weiping
Su, Jiabin
Gao, Xinjie
Yang, Heng
Weng, Ruiyuan
Ni, Wei
Gu, Yuxiang
The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title_full The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title_fullStr The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title_full_unstemmed The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title_short The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
title_sort microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013454/
https://www.ncbi.nlm.nih.gov/pubmed/35430804
http://dx.doi.org/10.1186/s40168-022-01255-6
work_keys_str_mv AT xiaoweiping themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT sujiabin themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT gaoxinjie themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT yangheng themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT wengruiyuan themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT niwei themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT guyuxiang themicrobiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT xiaoweiping microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT sujiabin microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT gaoxinjie microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT yangheng microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT wengruiyuan microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT niwei microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids
AT guyuxiang microbiotagutbrainaxisparticipatesinchroniccerebralhypoperfusionbydisruptingthemetabolismofshortchainfattyacids